UTRECHT, The Netherlands, Nov. 07, 2024 (GLOBE NEWSWIRE) — Today, ATNi launches the 5th edition of the Global Access to Nutrition Index, the largest yet, assessing the world’s 30 largest food and [...] Read more »
L’ATNi lance le 5e Indice mondial d’accès à la nutrition alors que l’industrie et les décideurs politiques sont aux prises avec la polycrise alimentaire
UTRECHT, Pays–Bas, 07 nov. 2024 (GLOBE NEWSWIRE) — Aujourd’hui, l’ATNi lance la 5e édition de l’Indice mondial d’accès à la nutrition, la plus importante à ce jour. [...] Read more »
ATNi veröffentlicht den 5. Global Access to Nutrition Index, während sich Industrie und Politik mit der Nahrungsmittelkrise als Teil der weltweiten Polykrise auseinandersetzen
UTRECHT, Niederlande, Nov. 07, 2024 (GLOBE NEWSWIRE) — ATNi veröffentlicht heute die fünfte und bisher größte Ausgabe des Global Access to Nutrition Index, der die 30 größten Lebensmittel– und [...] Read more »
ATNi lança 5º Índice Global de Acesso à Nutrição enquanto a indústria e os formuladores de políticas lutam contra a policrise alimentar
UTRECHT, Países Baixos, Nov. 07, 2024 (GLOBE NEWSWIRE) — Hoje, a ATNi lança a 5a edição do Índice Global de Acesso à Nutrição, o maior até o momento, avaliando [...] Read more »
Monica Lewinsky Visits Agnivesh Agarwal’s Primeks Medical, Advocates Against Cyberbullying in Istanbul
ISTANBUL, Oct. 31, 2024 (GLOBE NEWSWIRE) — World–renowned cyberbullying activist Monica Lewinsky visited Istanbul this October at the invitation of Agnivesh Agarwal, founder of Primeks Medical Clinics and Laboratories. Her [...] Read more »
Advanced Care Group Makes a Strong Entrance at Global Health Exhibition, Ready to Lead at Arab Health 2025
RIYADH, Saudi Arabia, Oct. 25, 2024 (GLOBE NEWSWIRE) — Advanced Care Group is making waves in the Middle Eastern healthcare market following a powerful debut at the Global Health Exhibition in Riyadh. From October 21 to 23, Advanced [...] Read more »
Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection
- REC–3964 is Recursion’s first new chemical entity developed using the RecursionOS.
- REC–3964 represents a novel, non–antibiotic approach with a unique mechanism of action that binds and blocks [...] Read more »
Angelini Pharma Enters Into An Exclusive Option Agreement With Cureverse to License Global Development and Commercialization Rights For A Novel and Innovative Clinical-Stage Brain Health Asset
- The agreement gives Angelini Pharma an option to exclusive licensing rights to develop and commercialize CV–011, a clinical Phase 1 investigational novel compound with broad [...] Read more »
Sabin Vaccine Institute Delivers Marburg Vaccines to Combat Outbreak in Rwanda
[Caption] Sabin Vaccine Institute delivered 700 doses of its Marburg vaccine to Rwanda on Oct. 5, 2024.
WASHINGTON, Oct. 05, 2024 (GLOBE NEWSWIRE) — The Sabin Vaccine Institute has provided [...] Read more »
Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
- First program to combine Recursion’s end–to–end suite of AI–enabled active learning modules, resulting in target identification to IND enabling studies in under [...] Read more »
Curium Announces Strategic Partnership with PeptiDream for Prostate Cancer Theranostics in Japan
- Collaboration to include the clinical development, regulatory filing, and commercialization in Japan of 177Lu–PSMA–I&T and 64Cu–PSMA–I&T
- Builds on long–standing [...] Read more »
Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders
JERUSALEM and MIAMI, Sept. 25, 2024 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX) (Entera), a leader in the development of orally delivered peptides, and OPKO Health, Inc. (NASDAQ: OPK) (OPKO) announced today [...] Read more »
Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
SALT LAKE CITY, Sept. 03, 2024 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced top–line results of the SYCAMORE trial, a [...] Read more »
Healthcare, Technology Leaders Gather in Johannesburg for Healthcare Innovation Summit Africa 2024
JOHANNESBURG, Aug. 23, 2024 (GLOBE NEWSWIRE) — Technology is revolutionizing healthcare in Africa, from enhancing patient care with electronic health records to enabling remote consultations via telemedicine. These advancements are [...] Read more »
Brains Bioceutical Deve Obter o Primeiro Certificado CEP do Mundo para Canabinóides, do European Directorate de Qualidade de Medicamentos e Cuidados de Saúde
SANDWICH, Reino Unido, Aug. 22, 2024 (GLOBE NEWSWIRE) — A Brains Bioceutical Corp. (BBC) alcançou um marco inovador ao fazer um dos primeiros pedidos de CEP (Certificação de Adequação) do mundo para [...] Read more »